Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study
Status:
Not yet recruiting
Trial end date:
2026-12-06
Target enrollment:
Participant gender:
Summary
CAREGIVER is a prospective, randomized, multicenter, open, five-arm study with unequal
allocation ratios of 1:1:2:1:2 (palbociclib : paclitaxel : palbociclib + paclitaxel :
carboplatin : carboplatin + paclitaxel). Study will be performed in untreated patients with
triple-negative breast cancer (TNBC). Potential candidates without previously established
diagnosis of TNBC will be included in a Pre-screening Phase, when a biopsy of breast tumor
will be taken to confirm the diagnosis of cancer, select patients with TNBC and collect
tissue for translational research.